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AbsTrACT
Objective To investigate the association between 
baseline disease activity and the occurrence of flares 
after adalimumab tapering or withdrawal in patients 
with rheumatoid arthritis (Ra) in sustained remission.
Methods The PReDiCTRa phase iV, randomised, 
double- blind (DB) study (imPact of Residual inflammation 
Detected via imaging Techniques, Drug levels, and 
Patient Characteristics on the Outcome of Dose Tapering 
of adalimumab in Clinical Remission Rheumatoid 
arThritis (Ra) Patients) enrolled patients with Ra 
receiving adalimumab 40 mg every other week who were 
in sustained remission ≥6 months. after a 4- week, open- 
label lead- in (Ol- li) period, patients were randomised 
5:1 to DB adalimumab taper (every 3 weeks) or 
withdrawal (placebo) for 36 weeks. The primary endpoint 
was the association between DB baseline hand and wrist 
MRi- detected inflammation with flare occurrence.
results Of 146 patients treated during the Ol- li 
period, 122 were randomised to taper (n=102) or 
withdrawal (n=20) arms. Patients had a mean 12.9 
years of active disease and had received adalimumab 
for a mean of 5.4 years (mean 2.2 years in sustained 
remission). Overall, 37 (36%) and 9 (45%) patients 
experienced a flare in the taper and withdrawal arms, 
respectively (time to flare, 18.0 and 13.3 weeks). none 
of the DB baseline disease characteristics or adalimumab 
concentration was associated with flare occurrence after 
adalimumab tapering. approximately half of the patients 
who flared regained clinical remission after 16 weeks of 
open- label rescue adalimumab. The safety profile was 
consistent with previous studies.
Conclusions approximately one- third of patients 
who tapered adalimumab versus half who withdrew 
adalimumab experienced a flare within 36 weeks. Time 
to flare was numerically longer in the taper versus 
withdrawal arm. Baseline MRi inflammation was not 
associated with flare occurrence.
Trial registration number nCT02198651, eudraCT 
2014-001114-26.
InTrOduCTIOn
The current treat- to- target recommendations for 
rheumatoid arthritis (RA) suggest starting treatment 
with conventional synthetic disease- modifying 
antirheumatic drugs (csDMARDs) as soon as 
possible and adjusting therapy if no improvement 
is observed by 3 months or if treatment target 
of sustained remission or low disease activity is 
not reached by 6 months; addition of a biologic 
DMARD (bDMARD) is suggested, especially if poor 
prognostic factors are present.1 2 Rapid implemen-
tation of bDMARDs leads to improved outcomes 
in RA,3 but after sustained clinical remission has 
been achieved, the question as to whether therapy 
should be adjusted arises. The European League 
Against Rheumatism (EULAR) and the American 
College of Rheumatology (ACR) suggest that after 
Key messages
What is already known about this subject?
 ► Current treatment recommendations suggest 
that after treatment target has been achieved, 
tapering of biologic disease- modifying 
antirheumatic drugs (bDMARDs) may be 
considered in patients with rheumatoid arthritis 
(RA) who are in stable, long- standing clinical 
remission.
 ► However, it is still uncertain as to which 
patients could benefit from tapering with a low 
risk of flaring.
What does this study add?
 ► The PREDICTRA study (ImPact of Residual 
Inflammation Detected via Imaging TEchniques, 
Drug Levels, and Patient Characteristics on 
the Outcome of Dose TaperIng of Adalimumab 
in Clinical Remission Rheumatoid ArThritis 
(RA) Patients) demonstrated that tapering of 
adalimumab was a viable option for a subset of 
patients (64%) with established RA who were 
in deep remission.
 ► Although rescue adalimumab therapy resulted 
in ≥50% of patients regaining disease control, a 
considerable proportion of patients (37%–50%) 
did not regain control despite 16 weeks of 
rescue adalimumab therapy.
How might this impact on clinical practice or 
future developments?
 ► Tapering bDMARDs is an option for a subset 
of patients who are in deep, long- standing 
remission, and in case of a flare, previous 
bDMARD dose can be reinstituted to help 
regain remission in some but not all patients.
 ► However, attempts to define this subset based 
on patient, clinical and imaging characteristics 
were not successful in this study, suggesting 
that additional research is needed.
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treatment target has been achieved, tapering of bDMARDs may 
be considered in patients who are in stable, long- standing clinical 
remission.1 2
However, the current evidence regarding bDMARD tapering 
or discontinuation (complete withdrawal) in patients with 
RA remains inconclusive. In controlled studies, 13%–81% of 
patients were able to maintain disease control after tapering or 
withdrawal of tumour necrosis factor (TNF) inhibitors, with 
higher percentages of patients failing among those with estab-
lished RA versus early RA.4–8 Other data on prognostic factors 
for flare after therapy tapering are limited, and reinstitution of 
standard TNF inhibitor dosing after a flare has been successful in 
regaining disease control in some studies,9–11 but not all studies 
have shown as favourable results.12
Imaging techniques such as MRI and ultrasound allow for 
accurate identification of subclinical inflammation, even in 
apparent clinical remission, and this inflammation predicts struc-
tural damage progression and may predict relapse in patients 
who are in clinical remission.11 13–16 MRI has been shown to 
identify signs of inflammation by synovitis and bone marrow 
oedema (BME, now known to be osteitis), as well as erosions not 
otherwise observed with conventional radiographs,17 in a high 
proportion of patients considered to be in clinical remission.18
The objective of the PREDICTRA study (ImPact of Residual 
Inflammation Detected via Imaging TEchniques, Drug Levels, 
and Patient Characteristics on the Outcome of Dose TaperIng of 
Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) 
Patients) was to investigate the association between residual base-
line disease activity detected by MRI and the occurrence of flares 
in patients with RA in persistent long- standing clinical remission 
who were randomised to an adalimumab dose tapering regimen 
or adalimumab withdrawal, which served as a control arm.
MeTHOds
Participants
PREDICTRA was a phase IV, randomised, double- blind (DB), 
parallel- group study conducted in 54 sites in Australia, Canada, 
Europe and the USA (registered per the WHO Trial Regis-
tration Data Set at www. clin ical tria lsre gister. eu; EudraCT 
2014-001114-26).
A detailed description of the study design and patient inclusion 
criteria has been previously published.19 Briefly, patients with 
RA who were receiving adalimumab 40 mg every other week 
(eow) for ≥12 months and who were in stable clinical remis-
sion, defined as 28- joint Disease Activity Score based on eryth-
rocyte sedimentation rate or C reactive protein (DAS28(ESR) or 
DAS28(CRP)) <2.6 for ≥6 months and DAS28(ESR) <2.6 at 
screening, were eligible to enter this study. Stable concomitant 
csDMARDs (≥12 weeks), oral corticosteroids (doses <10 mg/
day, ≥4 weeks) and non- steroidal anti- inflammatory drugs 
(NSAIDs ≥4 weeks) were permitted. Patients not taking metho-
trexate in a stable dose for ≥12 weeks prior to baseline could be 
enrolled (up to 20% of overall study population); once a limit 
of 20% on other csDMARDs or adalimumab monotherapy (no 
csDMARDs) was met, only patients receiving concomitant meth-
otrexate were allowed in the study. Exclusion criteria included 
current use of bDMARDs other than adalimumab and any 
medical condition precluding contrast- enhanced MRI.
study design and treatments
After a screening period of up to 28 days, patients were 
enrolled to a 4- week, open- label lead- in (OL- LI) period, during 
which patients continued to receive adalimumab 40 mg eow 
and persistent clinical remission was confirmed. Patients with 
DAS28(ESR) <2.6 who completed the 4- week OL- LI were 
randomised 5:1 to DB taper arm (adalimumab 40 mg every 3 
weeks) and withdrawal control arm (placebo) for 36 weeks. 
Patients who experienced a flare during the DB period entered 
an open- label rescue arm (flare week 0) and received open- label 
adalimumab 40 mg eow for up to 16 weeks (study visits at flare 
weeks 4, 10 and 16). Flare was defined as either DAS28(ESR) 
>2.6 and DAS28(ESR) increase >0.6 from DB baseline or 
DAS28(ESR) increase ≥1.2 from DB baseline, irrespective of 
absolute DAS28(ESR).
All participants were required to sign a written informed 
consent statement before the start of any study procedures.
endpoints
The primary endpoint was the association between DB baseline 
(MRI performed between OL- LI period weeks 0 and 4) hand 
and wrist synovitis, BME, and the composite of both as assessed 
using the OMERACT Rheumatoid Arthritis Magnetic Reso-
nance Imaging Score (RAMRIS) and flare occurrence in patients 
randomised to the adalimumab taper arm.
Key secondary endpoints have been previously described19 and 
included time to and proportion of patients with flare or who 
regained disease control following flare (defined as DAS28(ESR) 
<2.6 if DAS28(ESR) ≥2.6 at flare or as DAS28(ESR) decrease 
>1.2 if DAS28(ESR) <2.6 at flare), proportion of patients 
maintaining clinical remission through week 40, and association 
between occurrence of flares and DB baseline patient demo-
graphics, disease characteristics and adalimumab trough concen-
trations (taper arm only). In addition, change from DB baseline 
to week 40 (non- flared patients) or flare week 16 (flared patients) 
in clinical remission, Health Assessment Questionnaire Disability 
Index (HAQ- DI), 28- joint swollen joint count, 28- joint tender 
joint count, physician- reported and patient- reported outcome 
(PRO) measures, and RAMRIS scores were assessed in the taper 
and withdrawal arms. Anti- adalimumab antibodies were assessed 
in the taper and withdrawal arms; a patient was considered to be 
anti- adalimumab antibody- positive if they had antibody concen-
tration >20 ng/mL and the sample was collected within 30 days 
after an adalimumab dose.
The occurrence of adverse events (AEs) during the study and 
up to 70 days after discontinuation of study treatment was also 
collected.
statistical analyses
The sample size was based on the precision for estimating the 
OR for the occurrence of flare with baseline MRI score. Based 
on an assumed flare rate of 40%, a sample size of 100 patients 
in the tapering arm ensures a precision for the estimation, with 
the width of 95% CI no more than 0.19 for an OR of 1.1 and 
no more than 0.26 for an OR of 1.2. Under a 5:1 randomisa-
tion ratio (dose tapering vs withdrawal), 120 patients would be 
required to be randomised. Accounting for a 10%–20% discon-
tinuation rate during the OL- LI period, approximately 150 
patients would be required to be enrolled into the OL- LI period.
The analysis population for the OL- LI period included all 
patients receiving at least one dose of open- label adalimumab. 
The primary efficacy analysis population for the DB period 
included all patients receiving treatment during the DB period.
Logistic regression analyses with occurrence of flare as the 
dependent variable and MRI scores and other baseline charac-
teristics as independent variables in separate statistical models 
were conducted. Descriptive statistics including counts and 
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Figure 1 Patient disposition. *Two patients entered the DB period but were not treated during the OL- LI period. During the OL- LI period, five 
patients were not in remission; of these, two patients did not continue into the DB period, whereas three patients were randomised into the DB 
period in error (all were due to the baseline DAS28 score being entered incorrectly). †One patient discontinued after withdrawal of consent and was 
not treated during the OL- LI period. ‡ Other reasons included MRI refusal/not performed/problems, n=8; elevated DAS28/flare, n=4; did not meet 
randomisation criteria, n=1, protocol violation, n=1, family emergency, n=1; moved, n=1, patient request, n=1. §Other reasons included protocol 
violation, n=1; patient request after serious AE, n=1; patient unable to attend visits, n=1; final visit mistakenly reported as premature discontinuation, 
n=1. |1 patient was incorrectly entered and treated in the open- label rescue period. ¶Other reason was patient request. AE, adverse event; DAS28, 
28- joint Disease Activity Score; DB, double- blind; OL- LI, open- label, lead- in.
proportions with 95% CI and Kaplan- Meier estimates are 
provided. Last observation carried forward was used for imputa-
tion of missing data. For the DB period, missing values are only 
imputed up to the time when the patient entered the open- label 
rescue period.
Patient and public involvement
This research was done without any formal patient/patient organ-
isation involvement in study design, development of patient rele-
vant outcomes, interpretation of results, or the writing or editing 
of the manuscript.
resulTs
A total of 149 patients entered and 146 were treated with adali-
mumab in the OL- LI period (figure 1). Of these, 122 were in 
clinical remission at weeks 0 and 4 and were randomised to 
the taper (n=102) and withdrawal (n=20) arms. A total of 93 
(91%) patients in the taper arm and 19 (95%) patients in the 
withdrawal arm (including the rescue populations) completed 
the study. During the DB and rescue periods, the most common 
reasons for discontinuation of study were withdrawal of consent 
(n=4), other (n=5) and AEs (n=1).
Most patients in the OL- LI treated population were women 
(75%), with a mean (SD) duration of active disease of 12.9 
(10.0) years (n=142). Patients had received adalimumab for a 
mean (SD) of 5.4 (3.3) years and were in stable clinical remission 
for a mean (SD) of 2.2 (2.0) years (n=125) (table 1). All patients 
randomised to the DB period were on concomitant DMARDs 
at DB baseline, and 44% and 32% of patients had previously 
received or were receiving NSAIDs and steroids, respectively, at 
DB baseline.
db population
Overall, a numerically lower percentage of patients in the taper 
arm (37, 36%) than in the withdrawal arm (9, 45%) experi-
enced a flare by week 40 (figure 2A; inserts). Flare rates were 
13%, 27% and 35% in the taper arm and 10%, 35% and 40% 
in the withdrawal arm at weeks 12, 24 and 36, respectively. 
Flares occurred later in the taper arm than in the withdrawal 
arm; using Kaplan- Meier methods, 25% of the patients experi-
enced a flare after 18.0 weeks in the taper arm and 13.3 weeks 
in the withdrawal arm (first quartile; figure 2A). Due to the low 
number of flares in the study, the median time to flare was not 
reached in either arm.
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Table 1 Patient demographics and disease characteristics at baseline in the OL- LI treated population and at DB baseline in the DB population
Ol- lI treated population (n=146)
             db population
Taper arm (n=102) Withdrawal arm (n=20) randomised (n=122)
Women, n (%)* 109 (75) 79 (77) 12 (60) 91 (75)
Race, white, n (%)* 139 (97), n=143 97 (97), n=100 20 (100) 117 (98), n=120
Age, years* 59.6 (10.3) 59.2 (10.4) 62.7 (9.2) 59.7 (10.3)
Prior or concomitant NSAIDs, n (%)† 65 (45) 42 (41) 12 (60) 54 (44)
Prior or concomitant steroids, n (%)† 46 (32) 30 (29) 9 (45) 39 (32)
Concomitant steroids, n (%)† – 14 (14) 4 (20) 18 (15)
Prior or concomitant DMARDs, n (%)† 146 (100)‡ 102 (100) 20 (100) 122 (100)
Methotrexate dose, mg/week§ 13.6 (5.7), n=122 13.6 (5.6), n=85 11.7 (5.4), n=18 13.3 (5.6), n=103
DAS28(ESR) 1.8 (0.7) 1.7 (0.6) 1.6 (0.7) 1.7 (0.6)
DAS28(ESR) <2.6, n (%) 141 (97) 102 (100) 20 (100) 122 (100)
CDAI ≤2.8, n (%) 116 (79) 85 (83) 19 (95) 104 (85)
SDAI ≤3.3, n (%) 119 (82) 89 (87) 19 (95) 108 (89)
PtGA 8.7 (11.8) 6.8 (9.3) 4.3 (6.7) 6.4 (8.9)
PGA 3.3 (6.2) 3.8 (5.1) 2.6 (4.4) 3.6 (5.0)
PtGA pain 9.7 (11.0) 8.9 (11.9) 6.0 (8.8) 8.4 (11.5)
Synovitis RAMRIS¶ – 2.3 (2.2) 2.1 (1.6), n=19 2.3 (2.1), n=121
BME RAMRIS¶ – 1.6 (2.8) 2.1 (2.1) 1.7 (2.7)
Synovitis and BME composite RAMRIS¶ – 3.9 (4.1) 4.3 (3.3), n=19 4.0 (4.0), n=121
HAQ- DI 0.4 (0.5) 0.4 (0.5) 0.2 (0.3) 0.4 (0.5)
RAPID-3 3.3 (3.0), n=145 3.5 (3.3) 2.0 (2.4) 3.3 (3.2)
SF-36 PCS** – 49.8 (7.9), n=99 52.1 (6.7) 50.1 (7.8), n=119
SF-36 MCS** 54.0 (8.1), n=99 56.4 (5.0) 54.4 (7.7), n=119
FACIT- fatigue** 43.8 (6.1), n=100 47.6 (3.6) 44.4 (6.0), n=120
Data are mean (SD) unless otherwise noted.
*At baseline for all populations.
†Prior or concomitant DMARDs, NSAIDs and steroids are taken before or at baseline for the OL- LI population and before or at DB baseline for the DB population. Concomitant steroids include all medications that 
started prior to the first dose of study drug and continued to be taken after the first dose of study drug.
‡Overall, 145 patients had received prior conventional synthetic DMARDs (including methotrexate, chloroquine, hydroxychloroquine, sulfasalazine, gold formulations and/or leflunomide) and 38 patients had received 
prior biologic DMARDs (excluding adalimumab).
§Methotrexate taken at baseline for the OL- LI population and at DB baseline for the DB population.
¶MRI assessments were done during the OL- LI period and not at the OL- LI baseline.
**Not collected at OL- LI baseline.
BME, bone marrow oedema; CDAI, Clinical Disease Activity Index; DAS28(ESR), 28- joint Disease Activity Score based on erythrocyte sedimentation rate; DB, double- blind; DMARD, disease- modifying antirheumatic drug; 
FACIT, Functional Assessment of Chronic Illness Therapy; HAQ- DI, Health Assessment Questionnaire Disability Index; MCS, mental component summary; NSAID, non- steroidal anti- inflammatory drug; OL- LI, open- label 
lead- in; PCS, physical component summary; PGA, Physician Global Assessment of disease activity; PtGA, Patient Global Assessment of disease activity; RAMRIS, Rheumatoid Arthritis Magnetic Resonance Imaging Score; 
RAPID-3, Routine Assessment of Patient Index Data; SDAI, Simplified Disease Activity Index; SF-36, Short Form 36 Health Survey Questionnaire.
The primary endpoint analysis showed that baseline synovitis 
RAMRIS, BME RAMRIS, or the synovitis and BME composite 
RAMRIS were not associated with flare occurrence in the taper 
arm (figure 3). Similarly, none of the other assessed DB baseline 
patient characteristics or demographics was associated with a 
flare.
Clinical remission defined as DAS28(ESR) <2.6 was main-
tained by 86% (64 of 74) of patients in the taper arm and 85% 
(11 of 13) in the withdrawal arm who were still in the DB period 
at week 40 (table 2). As expected, patients who did not experi-
ence a flare during the study generally maintained or improved 
most secondary efficacy endpoints and PROs at week 40 in both 
the taper and withdrawal arms, suggesting long- term deep remis-
sion (online supplementary table S1). Overall, 76% (48 of 63) 
of patients in the taper arm and 82% (9 of 11) of patients in the 
withdrawal arm had normal HAQ- DI at week 40.
rescue population
Overall, 39 patients entered the rescue period (31 of 102 (30%) 
in the taper arm and 8 of 20 (40%) in the withdrawal arm). 
Among patients who flared, 38% (11 of 29) of patients in the 
taper arm and 50% (4 of 8) of patients in withdrawal arm 
regained disease control after 16 weeks of open- label adalim-
umab rescue therapy (figure 2B; inserts). Time to regain disease 
control (first quartile based on Kaplan- Meier methods) was 4.1 
weeks in the taper arm and 10.6 weeks in the withdrawal arm 
(figure 2B). Approximately half of the patients who flared (13 
of 29 in the taper arm and 4 of 8 in the withdrawal arm) were 
in clinical remission, defined as DAS28(ESR) <2.6, Simplified 
Disease Activity Index ≤3.3 and Clinical Disease Activity Index 
≤2.8, at flare week 16.
As expected, most clinical activity and PRO measures wors-
ened from DB baseline to flare week 0, including individual 
DAS28(ESR) components (online supplementary table S2), and 
generally remained worsened at flare week 16 in both the taper 
and withdrawal arms despite rescue therapy (online supplemen-
tary table S1). Overall, 52% (15 of 29) of patients in the taper 
arm and 71% (5 of 7) of patients in the withdrawal arm had 
normal HAQ- DI score at flare week 16.
Other secondary endpoints
No associations between adalimumab concentrations at DB 
baseline and the occurrence of flare by week 40 were observed 
in the taper arm (mean (SD) adalimumab, 7.8 (4.9) μg/mL in 
the 37 flared patients vs 8.0 (4.6) μg/mL in the 64 non- flared 
patients) or in the withdrawal arm (mean (SD) adalimumab, 8.8 
(3.9) μg/mL in the 9 flared patients vs 7.7 (4.9) μg/mL in the 11 
non- flared patients).
Anti- adalimumab antibodies were detected in 3.3% of patients 
overall; 2.9% (3 of 102) of patients in the taper arm and 5.0% (1 
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Figure 2 (A) Percentage of patients who flared and time from DB baseline to flare in the taper and withdrawal arms, and (B) percentage of patients 
who regained disease control and time from flare to regain of disease control in the taper and withdrawal arms. Last observation carried forward 
analysis. Flare was defined as either DAS28(ESR) >2.6 and DAS28(ESR) increase >0.6 from DB baseline or DAS28(ESR) increase ≥1.2 from DB baseline, 
irrespective of absolute DAS28(ESR). Regain of disease control was defined as DAS28(ESR) <2.6 if DAS28(ESR) ≥2.6 at flare and as DAS28(ESR) 
decrease >1.2 if DAS28(ESR) <2.6 at flare. DAS28(ESR), 28- joint Disease Activity Score based on erythrocyte sedimentation rate. DB, double- blind.
of 20) in the withdrawal arm were positive for anti- adalimumab 
antibodies.
safety
During the OL- LI period, 25% of patients experienced AEs and 
3% experienced serious AEs (table 3). Similar proportion of 
patients experienced AEs during the DB period in the taper 
(61%), withdrawal (60%) and rescue (62%) arms; a greater 
percentage of patients in the rescue arm experienced serious 
AEs (8%) than in the taper (1%) or withdrawal (0%) arms. 
Most serious AEs were considered not to be related to treat-
ment and included four events in the OL- LI period (pneu-
monia, atrial fibrillation, comminuted fracture and transient 
ischaemic attack), one event in the taper arm (breast cancer, 
possibly related to study drug) and three events in the rescue 
arm (pleural effusion (possibly related to study drug), retinal 
vein occlusion and osteoarthritis). No opportunistic infections, 
tuberculosis, non- melanoma skin cancer, lymphoma, demy-
elinating disorders or deaths were observed during the study 
(table 3).
dIsCussIOn
The PREDICTRA study demonstrated that baseline MRI measures 
of inflammation were not associated with flare occurrence after 
tapering of adalimumab. The enrolled patients were selected for 
sustained clinical remission in the OL- LI period (unlike previous 
studies where history of remission or single time- point remis-
sion was the inclusion criteria) and had low inflammation on 
MRI at baseline, and this homogeneity in low scores may have 
limited the ability of this study to demonstrate a relationship 
between objectively assessed MRI inflammation and flare. This 
is in contrast to previous studies that demonstrated synovitis was 
associated with bDMARD tapering failure.11 15 16 However, all 
these studies were smaller (≤77 patients) and usually in patients 
with earlier disease.
The PREDICTRA study also assessed whether tapering or 
withdrawal of adalimumab therapy is feasible in patients with 
established RA who were in persistent, long- standing remission. A 
control (withdrawal) arm was included as a study design element 
to ensure the objectivity of flare assessments in the primary study 
arm. Our findings demonstrated that approximately one- third of 
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Figure 3 DB baseline parameters and occurrence of flare among patients in the taper arm. *Excluding adalimumab. ACPA, anticitrullinated peptide 
antibody; bDMARDs, biologic disease- modifying antirheumatic drugs; BME, bone marrow oedema; CRP, C reactive protein; csDMARDs, conventional 
synthetic disease- modifying antirheumatic drugs; DAS28(ESR), 28- joint Disease Activity Score based on erythrocyte sedimentation rate; DB, double- 
blind; HAQ- DI, Health Assessment Questionnaire Disability Index; RAMRIS, Rheumatoid Arthritis MRI Score; RF, rheumatoid factor.
Table 2 Percentage of patients who maintained clinical remission 
at week 40 in DB treated patients who were still in the DB period at 
week 40
Taper arm (n=102) Withdrawal arm (n=20)
DAS28(ESR) <2.6 64/74 (86.5) 11/13 (84.6)
SDAI ≤3.3 57/74 (77.0) 12/13 (92.3)
CDAI ≤2.8 56/74 (75.7) 12/13 (92.3)
LOCF analysis.
CDAI, Clinical Disease Activity Index; DAS28(ESR), 28- joint Disease Activity Score 
based on erythrocyte sedimentation rate; DB, double- blind; LOCF, last observation 
carried forward; SDAI, Simplified Disease Activity Index.
patients who tapered adalimumab to every 3 weeks compared 
with half who completely withdrew adalimumab therapy expe-
rienced a flare within 36 weeks. Time to flare was shorter in the 
withdrawal arm versus the taper arm. After a flare, ≥50% of 
patients regained disease control with up to 16 weeks of adali-
mumab rescue therapy; however, a considerable proportion of 
patients (37% in the taper arm and 50% in the withdrawal arm) 
did not. These results suggest that tapering of bDMARDs is 
only a viable option for a subset of patients. Attempts to define 
this subset of patients based on baseline clinical and imaging 
characteristics associated with the occurrence of flare were not 
successful in this study.
As expected, the enrolled patients in sustained clinical remis-
sion on adalimumab 40 mg eow had low clinical disease activity 
and low inflammation on MRI at baseline. These endpoints 
were maintained or improved from DB baseline to week 40 in 
both the taper and withdrawal arms, suggesting deep remission 
and demonstrating that, although the flare criteria were based 
on disease activity, the lack of flare was also associated with 
maintenance of other endpoints. In contrast, among patients 
who flared, most of these endpoints worsened from DB baseline 
to flare week 16, regardless of adalimumab rescue therapy in 
both arms. These findings further support the notion that not 
all patients do well after bDMARD tapering or withdrawal, or 
regain disease control if reinitiation of therapy is required, espe-
cially with long- standing disease.
Our results align with the current EULAR and ACR treatment 
guidelines that suggest tapering of bDMARDs may be consid-
ered in patients who are in stable, long- standing clinical remis-
sion.1 2 However, a reported 21%–100% of patients experience 
a relapse within 12 months of dose reduction.20 Furthermore, 
significantly more short- lived flares (73% vs 27% of patients) and 
radiographic progression at 18 months were observed with dose 
tapering versus dose continuation in an open- label, randomised 
RA study of TNF inhibitors.21 Because many patients express a 
desire to taper therapy or take a ‘drug holiday’ when in remis-
sion,22 it is essential to identify those who are candidates for 
therapy tapering. In general, patients with early RA or those with 
deeper or longer clinical remission are less likely to experience 
disease flare after bDMARD tapering.23 The latter is supported 
by the PREDICTRA data, as 64% of patients with established RA 
(mean disease duration of 12.9 years) who were in deep, long 
remission (mean DAS28(ESR) of 1.7) for a mean of 5.4 years did 
not experience a flare after bDMARD tapering. Although no vari-
able was associated with flare occurrence in our study, baseline 
DAS28(ESR) was a predictor of remission (DAS28(ESR) <2.6) 
after withdrawal of adalimumab therapy in the observational 
Humira discontinuation without functionaland radiographic 
damage progressioN follOwing sustained Remission (HONOR) 
study. The study also identified DAS28(ESR) ≤2.16 as a critical 
cut- off point for predicting flare; 78% of patients with mean 
DAS28(ESR) ≤2.16 at the time of adalimumab withdrawal main-
tained remission after 6 months (vs 2% for DAS28(ESR) >2.16, 
<2.6).24 However, mean disease duration (6.6 vs 12.9 years), 
adalimumab treatment duration (1.2 vs 5.4 years) and metho-
trexate dose (8.1 vs 13.3 mg/week) were lower in HONOR study 
patients than in patients in the PREDICTRA study.
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Table 3 Incidence of AEs during OL- LI period and DB randomised period
Ae, n (%)
Ol- lI treated population
(n=146)
       db population
rescue population (n=39)Taper arm (n=102) Withdrawal arm (n=20)
Any AE 36 (25) 62 (61) 12 (60) 24 (62)
Serious AE* 4 (3) 1 (1) 0 3 (8)
Any AE leading to discontinuation† 1 (1) 2 (2) 0 0
Any AE related to study drug 11 (8) 26 (25) 5 (25) 9 (23)
Any serious AE related to study drug* 0 1 (1) 0 1 (3)
Infection 11 (8) 34 (33) 8 (40) 15 (38)
  Serious infection 1 (1)‡ 0 0 0
  Opportunistic infections§ 0 0 0 0
  Tuberculosis 0 0 0 0
Malignancy¶ 0 1 (1)** 0 0
NMSC 0 0 0 0
Lymphoma 0 0 0 0
Demyelinating disorder 0 0 0 0
Death 0 0 0 0
In the OL- LI population, a treatment- emergent AE was defined as any AE with an onset date on or after the first dose of study drug and before the first DB dose or up to 70 days 
after the last dose if the patient discontinued prematurely.
In the DB population, a treatment- emergent AE was defined as any AE with an onset date on or after the first DB dose and before the open- label rescue period or up to 70 days 
after the last dose of study drug if the patient discontinued prematurely from the DB period.
In the rescue population, a treatment- emergent AE was defined as any AE with an onset date on or after the first dose of open- label rescue adalimumab and up to 70 days after 
the last dose of study drug.
*Serious AEs (and serious AEs possibly related to study drug as assessed by the investigator) included atrial fibrillation, pneumonia, comminuted fracture and transient ischaemic 
attack (OL- LI treated population), breast cancer (possibly related) (DB taper arm), and retinal vein occlusion, osteoarthritis and pleural effusion (possibly related) (rescue 
population).
†AEs leading to discontinuation included herpes zoster (OL- LI treated population) and breast cancer and cough (DB taper arm).
‡Pneumonia.
§Excluding oral candidiasis and tuberculosis.
¶Other than lymphoma, hepatosplenic T- cell lymphoma, leukaemia, NMSC or melanoma.
**Breast cancer.
AE, adverse event; DB, double- blind; NMSC, non- melanoma skin cancer; OL- LI, open- label lead- in.
The mean serum adalimumab concentrations at DB base-
line were similar in patients who flared and did not flare in 
both arms, demonstrating no association between adalimumab 
concentration and the occurrence of flare by week 40. Neither 
adalimumab serum concentrations nor baseline antibody status 
was predictive of flare after tapering or withdrawal. Overall, the 
incidence of AEs and serious AEs was low, and the adalimumab 
safety profile was consistent with that reported previously.25
The strengths of this randomised, placebo- controlled DB study 
included that it only enrolled patients with established RA (mean 
12.9 years of active disease) who were in long- standing remis-
sion with adalimumab therapy and addressed a clinical question 
relevant for the field. Other strengths included inclusion of a 
withdrawal arm that served as a control and established differ-
ences between tapering and completely withdrawing therapy, 
as well as an open- label rescue arm that provided an opportu-
nity to assess the effectiveness of retreatment with adalimumab. 
Limitations of the study include a restricted and relatively small 
patient population (<150 patients with established RA in long- 
term remission), limited trial duration and time to assess disease 
control after 16 weeks. Furthermore, the baseline inflammation 
was low, which limited the ability to test the performance of 
MRI in this population of patients in deep, long- term remission.
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